Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

Ferring Pharmaceuticals461 enrolled

Overview

The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).

Study Type

OBSERVATIONAL

Enrollment

461

Conditions

Advanced Prostate Cancer

Interventions

DegarelixDRUG

According to medical practice

LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)DRUG

According to medical practice

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC) * Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment Exclusion Criteria: * Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline. * Participation in a clinical trial at baseline and during the follow-up period

Locations (1)

Investigational site (there may be other sites in this country)

Rottweil, Germany

Outcomes

Primary Outcomes

Level of urologist's knowledge of patients' medical history at the point of decision making and during Androgen Deprivation Therapy (ADT)

Measured by questionnaires by quantifying the frequency of urologists' entries

Time frame: Up to 4 years

Level of urologist's knowledge of patients' comorbidities at the point of decision making and during ADT

Measured by questionnaires by quantifying the frequency of urologists' entries

Time frame: Up to 4 years

Level of urologist's knowledge of patients' concomitant medications at the point of decision making and during ADT

Measured by questionnaires by quantifying the frequency of urologists' entries

Time frame: Up to 4 years

Level of urologist's knowledge of patients' risk factors at the point of decision making and during ADT

Measured by questionnaires by quantifying the frequency of urologists' entries

Time frame: Up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.